A study by Dudnik et al., which evaluated PD-L1 expression in 39 BRAF-mutant NSCLC patients, also suggested that BRAF mutation is associated with a high level of PD-L1 expression regardless of being the V600E subtype or not [28]. The gene discussed is BRAF; the disease is non-small cell lung carcinoma.